MedPath

天津梅花生物医药科技有限公司

Ownership
-
Established
1981-07-15
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

25

NMPA:25

Drug Approvals

Venlafaxine Hydrochloride Sustained-Release Capsules

Product Name
盐酸文拉法辛缓释胶囊
Approval Number
国药准字H20254342
Approval Date
May 27, 2025
NMPA

Lornoxicam for Injection

Product Name
注射用氯诺昔康
Approval Number
国药准字H20254107
Approval Date
May 13, 2025
NMPA

Salbutamol Sulfate Inhalation Solution

Product Name
吸入用硫酸沙丁胺醇溶液
Approval Number
国药准字H20244949
Approval Date
Sep 19, 2024
NMPA

Compound Ipratropium Bromide Solution for Inhalation

Product Name
吸入用复方异丙托溴铵溶液
Approval Number
国药准字H20243556
Approval Date
Apr 24, 2024
NMPA

Ipratropium Bromide Solution for Inhalation

Product Name
吸入用异丙托溴铵溶液
Approval Number
国药准字H20234472
Approval Date
Nov 14, 2023
NMPA

Galanthamine Hydrobromide Orally Disintegrating Tablets

Product Name
氢溴酸加兰他敏口腔崩解片
Approval Number
国药准字H20080769
Approval Date
Nov 3, 2023
NMPA

Ambzoxol Hydrochloride Granules

Product Name
盐酸氨溴索颗粒
Approval Number
国药准字H20184144
Approval Date
Mar 7, 2023
NMPA

Ambzoxol Hydrochloride Granules

Product Name
盐酸氨溴索颗粒
Approval Number
国药准字H20184143
Approval Date
Mar 7, 2023
NMPA

Roxithromycin Dispersible Tablets

Product Name
罗红霉素分散片
Approval Number
国药准字H20184132
Approval Date
Mar 7, 2023
NMPA

Roxithromycin Tablets

Product Name
罗红霉素片
Approval Number
国药准字H20174103
Approval Date
Jul 5, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.